Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) traded down 7.1% on Wednesday . The stock traded as low as $1.77 and last traded at $1.83. 51,247 shares changed hands during trading, an increase of 551% from the average session volume of 7,871 shares. The stock had previously closed at $1.97.
Cyclerion Therapeutics Stock Performance
The business’s fifty day moving average price is $2.72 and its 200 day moving average price is $2.79.
Cyclerion Therapeutics Company Profile
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
Featured Stories
- Five stocks we like better than Cyclerion Therapeutics
- Financial Services Stocks Investing
- Top-Performing Non-Leveraged ETFs This Year
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- What is the S&P 500 and How It is Distinct from Other Indexes
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
